Focused On-demand Library for Baculoviral IAP repeat-containing protein 7

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q96CA5

UPID:
BIRC7_HUMAN

ALTERNATIVE NAMES:
Kidney inhibitor of apoptosis protein; Livin; Melanoma inhibitor of apoptosis protein; RING finger protein 50; RING-type E3 ubiquitin transferase BIRC7

ALTERNATIVE UPACC:
Q96CA5; Q9BQV0; Q9H2A8; Q9HAP7

BACKGROUND:
The protein Baculoviral IAP repeat-containing protein 7, with alternative names such as Kidney inhibitor of apoptosis protein and Melanoma inhibitor of apoptosis protein, is crucial for apoptosis regulation. It protects against apoptosis induced by TNF and chemical agents, and promotes NK cell-mediated killing. Its function is facilitated by the inhibition of caspases and activation of MAPK pathways, highlighting its complex role in cell survival mechanisms.

THERAPEUTIC SIGNIFICANCE:
The intricate role of Baculoviral IAP repeat-containing protein 7 in cell survival and death pathways positions it as a key target for therapeutic intervention. Its ability to regulate apoptosis and cell proliferation presents unique opportunities for the development of targeted therapies in diseases where these processes are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7672 of 8789